Churchill Hospital
Oxford, United Kingdom
35 recruiting
Showing 1–20 of 35 trials
Recruiting
Phase 3
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
Kidney Disease, Chronic
Boehringer Ingelheim11,000 enrolled399 locationsNCT06531824
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Relapsed or Refractory Multiple Myeloma (RRMM)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company440 enrolled138 locationsNCT06615479
Recruiting
Phase 3
A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
Diabetes Mellitus, Type 1Impaired Hypoglycemic AwarenessSevere Hypoglycemia
Vertex Pharmaceuticals Incorporated52 enrolled29 locationsNCT04786262
Recruiting
Phase 3
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
Diabetes Mellitus, Type 1
Eli Lilly and Company300 enrolled129 locationsNCT07222332
Recruiting
Phase 1
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Hoffmann-La Roche137 enrolled31 locationsNCT05091424
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Metastatic Breast Cancer
Hoffmann-La Roche230 enrolled187 locationsNCT05894239
Recruiting
Phase 4
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Chronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma
Eli Lilly and Company279 enrolled36 locationsNCT06876662
Recruiting
Phase 3
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Small Cell Lung Cancer
Daiichi Sankyo540 enrolled230 locationsNCT06203210
Recruiting
Phase 4
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Chronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma
Eli Lilly and Company787 enrolled38 locationsNCT06876649
Recruiting
Phase 3
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Leukemia
Daiichi Sankyo700 enrolled292 locationsNCT06578247
Recruiting
Phase 3
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
Hodgkin Lymphoma
University College, London1,042 enrolled69 locationsNCT04685616
Recruiting
Phase 3
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Metastatic HER2-positive Breast Cancer
Jazz Pharmaceuticals550 enrolled166 locationsNCT06435429
Recruiting
Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Multiple Myeloma
Pfizer492 enrolled273 locationsNCT06152575
Recruiting
Not Applicable
HIFU Ablation of Soft Tissue Sarcoma
Soft Tissue SarcomaDesmoid Tumors
Oxford University Hospitals NHS Trust10 enrolled1 locationNCT05111964
Recruiting
Phase 2Phase 3
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
Ovarian NeoplasmsColorectal NeoplasmsUrinary Bladder Neoplasm+8 more
Cancer Research UK30 enrolled27 locationsNCT05786716
Recruiting
Phase 2Phase 3
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
MalignancyMelanomaCancer+8 more
Cancer Research UK30 enrolled27 locationsNCT05770544
Recruiting
Phase 2Phase 3
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
MalignancyMelanomaCancer+7 more
Cancer Research UK30 enrolled27 locationsNCT05770102
Recruiting
Phase 2Phase 3
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
CancerRenal Cell CarcinomaLymphoma+8 more
Cancer Research UK30 enrolled27 locationsNCT05770037
Recruiting
Phase 2Phase 3
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
MalignancyGastric CancerSoft Tissue Sarcoma+8 more
Cancer Research UK30 enrolled17 locationsNCT06988475
Recruiting
Phase 2Phase 3
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
MelanomaCarcinoma, Non-Small Cell LungOvarian Neoplasms+9 more
Cancer Research UK30 enrolled16 locationsNCT05768178